Mankind Pharma Q4 PAT Jumps 30%, FY26 Revenue Crosses Rs 14,000 Crore Mark
New Delhi: Mankind Pharma on Monday reported a 30.4 per cent rise in consolidated profit after tax (PAT) for the fourth quarter of FY26 at Rs 559 crore, while the company's annual revenue crossed Rs 14,000 crore for the first time during FY26.
The company posted consolidated revenue from operations of Rs 3,443 crore for Q4 FY26, registering an 11.8 per cent year-on-year growth compared to Rs 3,079 crore in the corresponding quarter last year. Domestic revenue rose 13.4 per cent to Rs 2,886 crore, while export revenue increased 4.2 per cent to Rs 557 crore.
Adjusted EBITDA for the quarter stood at Rs 933 crore with adjusted EBITDA margin improving 400 basis points year-on-year to 27.1 per cent. PAT margin also improved by 230 basis points to 16.2 per cent, while diluted EPS increased 30.3 per cent year-on-year to Rs 13.4.
For the full financial year 2025-26, Mankind Pharma reported revenue from operations of Rs 14,278 crore, up 17 per cent from Rs 12,207 crore in FY25. Domestic revenue for FY26 stood at Rs 12,217 crore, reflecting 14.4 per cent growth, while exports surged 34.5 per cent to Rs 2,061 crore.
Annual adjusted EBITDA stood at Rs 3,629 crore with adjusted EBITDA margin of 25.4 per cent. The company’s FY26 PAT came at Rs 1,938 crore, down 3.4 per cent year-on-year, while diluted EPS declined 5.7 per cent to Rs 46.3. Cash EPS, however, rose 5.6 per cent to Rs 68.1.
Commenting on the performance, Vice Chairman and Managing Director Rajeev Juneja said the company continued to strengthen its scale and specialization through four key pillars including base business, specialty chronic portfolio, OTC business and super specialty BSV portfolio to drive long-term growth.
According to the company, the domestic business excluding consumer healthcare grew around 13 per cent during the quarter, supported by double-digit growth in chronic therapies and strong performance in the BSV specialty business. Cardiac therapy recorded 14.7 per cent growth, while anti-diabetes business grew 11.6 per cent.
The company also highlighted sequential recovery in key acute therapies including gastro and VMN segments. Focus brands such as Telmikind family, Lipirose and Statpure recorded healthy growth during the quarter, while the Glizid brand family crossed Rs 230 crore in MAT March 2026.
Mankind Pharma’s BSV portfolio also delivered strong performance with brands including Foligraf, HMG, Ossopan and Lactare reporting significant growth. Anti-D maintained 100 per cent market share while growing 10 per cent. In the consumer healthcare segment, revenue grew 20 per cent year-on-year during Q4 FY26, driven by strong demand for brands including Manforce, Prega News, Gas-O-Fast and Nimulid. The company said modern trade and e-commerce contribution increased to 13 per cent in FY26 from 9 per cent in FY25, supported by 57 per cent growth.
International business recorded muted growth of 4 per cent during the quarter due to geopolitical headwinds. The company also launched four new products in FY26, taking the total number of products launched in the US market to 48.Mankind Pharma further stated that it has maintained the number one rank in prescription share over the last nine years with prescription share of 15.1 per cent.
The company currently operates 32 manufacturing facilities across India and has seven dedicated R&D centres supported by more than 750 scientists. Its field force includes over 18,500 professionals with reach extending to more than five lakh doctors across urban and rural markets.
According to the company’s press release, Mankind Pharma will host its earnings conference call on May 20, 2026.
